Ibruxen (Ibrutinib INN) 140 mg

£0.00

Ibruxen, containing Ibrutinib, the International Nonproprietary Name (INN) equivalent to Ibrutinib, is mainly prescribed for various blood cancers such as chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström’s macroglobulinemia. Operating as a Bruton’s tyrosine kinase (BTK) inhibitor, Ibruxen obstructs the function of BTK, a protein pivotal for cancer cell survival and proliferation. The typical recommended dose of Ibruxen is 140 mg administered orally once daily, with or without food. Patients might encounter adverse effects like diarrhea, fatigue, nausea, bruising, and infections. To effectively manage potential side effects and ensure treatment efficacy, close monitoring and regular medical check-ups are crucial throughout the course of Ibruxen therapy.

Add to wishlist
Share

    Indications: Ibrutinib (INN) 140 mg is prescribed for various hematologic cancers, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), Waldenström’s macroglobulinemia (WM), marginal zone lymphoma (MZL), and chronic graft-versus-host disease (cGVHD).

    Pharmacology: Ibrutinib inhibits Bruton’s tyrosine kinase (BTK), a crucial signaling molecule in B-cell receptor pathways, essential for malignant B-cell survival and proliferation.

    Dosage and Administration: The standard dose is 140 mg once daily, preferably taken at the same time daily, with or without food.

    Interactions: Ibrutinib may interact with medications metabolized by CYP3A4 and CYP2D6 enzymes, necessitating disclosure of all medications to healthcare providers.

    Side Effects: Common side effects include diarrhea, fatigue, musculoskeletal pain, nausea, rash, bruising, and upper respiratory tract infections. Serious effects may include bleeding, infections, atrial fibrillation, hypertension, and liver toxicity.

    Precautions and Warnings: Patients should be monitored for increased bleeding and infections, as well as atrial fibrillation, hypertension, and liver toxicity risks.

    Overdose Effects: Overdose management involves supportive measures, as there’s no specific antidote. Treatment focuses on addressing symptoms.

    Product Name

    Ibruxen

    Generic Name

    Ibrutinib INN

    Formulation

    Capsule

    Available Pack size

    120 Capsules

    Strengths

    140 mg

    Reviews

    There are no reviews yet.

    Be the first to review “Ibruxen (Ibrutinib INN) 140 mg”